Early detection is key
75% of PAD patients are asymptomatic and are not aware of their risk. Current Ankle-Brachial Index (ABI) testing methods present challenges for both medical staff and patients.
Early PAD detection breakthrough
UltraSense is a disruptive ultrasound technology combined with an AI platform that provides clinicians with the insight needed for appropriate treatment and prevention. Our patented system can also be used to measure and record ankle/toe arterial flow during PAD Endovascular procedures, confirming revascularization.
Accuracy and sensitivity
- Proprietary multi-element ultrasound technology
- Advanced AI-driven algorithms
- Proprietary stochastic resonance technology to boost signal even for low flow states
Ease of use
- Ultrasound accuracy with oscillometry convenience
- Automatic blood vessel acquisition
- Enhanced patient comfort and experience
- Eliminates test variability
Lower cost of care
- Decreased medical staff time
- Minimal training requirements
- Adherence to CMS guidelines
- Expansion of patient screening to primary care